Andrx considers Altocor name change
Executive Summary
Andrx is considering changing the name of the extended-release statin Altocor (lovastatin) to Altoprev. FDA approved the name Altoprev in an Aug. 20 1letter. Andrx submitted the sNDA with the proposed name change Dec. 5, 2002...
You may also be interested in...
Andrx changing Altocor name
Andrx is in discussions with FDA to market Altocor (lovastatin extended-release) under a new name "to avoid possible confusion in the marketplace." Company says name change is unrelated to Kos' lawsuit alleging a likelihood of confusion with its cholesterol-lowering agent Advicor (niacin/lovastatin). FDA already has approved Altoprev as an alternative brand for Altocor (1"The Pink Sheet" Sept. 15, 2003, In Brief)...
Vaccine Company CEOs Face Supply Probe In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Trial Shows Lateral Flow Antibody Testing Could Be Used To Assess COVID-19 Vaccine Efficacy
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: